

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

Danelle Buchman

Danelle Buchman has served as the Executive Director of the Hospice & Palliative Care Network of Maryland since January 2013. The Network is the state association for hospice providers, and its membership includes the majority of hospice providers in the state of Maryland. In her role as Executive Director, Danelle oversees all operating activities, including management of committees, educational programs and advocacy efforts.

Prior to coming to the Network, Danelle worked at United Way of Central Maryland. Previous employers include the American Cancer Society, the Maryland Affiliate of Susan G. Komen, and United States Senator Barbara Mikulski's Washington D.C. office.

Danelle earned a Bachelor's degree from the College of William and Mary. She resides in Howard County with her husband and two children.

Kevin J. Cullen, M.D.

Kevin J. Cullen, M.D., is Director of the University of Maryland Marlene and Stewart Greenebaum Cancer Center. Dr. Cullen, who specializes in head and neck cancer, is a professor of medicine at the University of Maryland School of Medicine and is head of its Program in Oncology. He came to the University of Maryland in January 2004.

A graduate of Dartmouth College and Harvard Medical School, Dr. Cullen completed his internship and residency at Beth Israel Hospital in Boston and received additional training at the National Cancer Institute. He served as interim director of the Lombardi Cancer Center at Georgetown University from October 2000 to September 2002 and was professor of medicine, oncology and otolaryngology at Georgetown University School of Medicine.

Dr. Cullen's research interests include cellular factors that promote the growth of cancer and molecular mechanisms that make some cancers resistant to treatment with chemotherapy. He is the author of numerous journal publications and has served on review panels for the National Cancer Institute, the Veterans Administration Research Program and other organizations. His honors include a special achievement award from the National Cancer Institute.

In 2008, the University of Maryland Greenebaum Cancer Center received NCI Cancer Center designation. This year it was ranked 11 of more than 900 cancer centers in America by *U.S. News and World Report*.

Outside of the University of Maryland, Dr. Cullen serves on the external advisory boards of several NCI designated cancer centers. He has chaired two working groups for the NCI and is a member of the national board of directors of the American Cancer Society and in 2011 was appointed by President Barak Obama to the National Cancer Advisory Board.

Diane M. Dwyer, M.D.

After completing Dartmouth Medical School and residency in Internal Medicine at the University of California San Francisco in 1981, Dr. Dwyer worked as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention for two years assigned to the Oklahoma State Health Department.

In 1983, Dr. Dwyer began working as a Public Health Physician in communicable diseases and in the AIDS program at the Baltimore City Health Department. She joined the Maryland Department of Health

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

and Mental Hygiene (DHMH) in 1988, working in outbreak investigation, immunization, infection control, and communicable disease surveillance. She became the Maryland State Epidemiologist in 1995 and the Director of Epidemiology and Disease Control Program in 1997.

Since 2000, she has been the Medical Director in the Center for Cancer Prevention and Control at the DHMH and oversees the Maryland Cancer Registry, cancer surveillance, and the Cigarette Restitution Fund cancer prevention and screening programs for colorectal, oral, prostate, and skin cancers.

Joanne H. Ebner, R.N., B.S.N., T.T.S.

Joanne H. Ebner, R.N., B.S.N., T.T.S. received her diploma in nursing at Illinois Masonic Medical Center School of Nursing in Chicago, Illinois and completed her Bachelor of Science in Nursing at College of Notre Dame of Maryland. Her nursing practice began in the Chicago area in Orthopedics and Home Health Nursing. Relocation to the Annapolis area brought her to Anne Arundel Medical Center where she continued her work in Medical-Surgical and Oncology Nursing. A move to Virginia resulted in a turning point in her career where she worked with the Department of Federal Occupational Health, a division of the U.S. Public Health Service where she specialized and earned certification in Occupational Health Nursing. After a fortunate return to Annapolis, she served as Department Head of Occupational Health Services, Infection Control Officer and assisted with Health Promotion/Disease Prevention activities at the U.S. Naval Academy Medical Clinic. She returned to Anne Arundel Medical Center where she has worked for the Employee Health Service and presently is the Coordinator for the Cancer Prevention Program/Nicotine Dependence Program. She is a certified Tobacco Treatment Specialist through the Mayo Clinic Nicotine Dependence Program.

Kira L. Eyring

Kira L. Eyring was appointed to the position of Health Systems Director for the American Cancer Society's Maryland region in 2011. In this role, she works with the largest hospitals and cancer centers in Baltimore to ensure American Cancer Society opportunities are provided to patients, caregivers and employees of the healthcare system. She began her career with the Society in 2001 as a Cancer Control Specialist, collaborating with community partners to educate about the detection and prevention of cancer. In 2005 she became the Regional Mission Delivery Director. Eyring collaborates with community health partners to reach thousands of cancer patients, their families and caregivers each year. Other responsibilities include directing regional efforts to educate and engage the public about the Society's recommended cancer screening guidelines, nutrition and physical activity, and the impact of tobacco cessation. She is also a member of the Maryland Cancer Collaborative Steering Committee, and co-chair of the Collaborative's Subcommittee on Palliative Care.

Seeking to expand the Society's impact in reaching cancer patients, Eyring has led efforts to build collaborative relationships with hospitals accredited by the American College of Surgeons and healthcare facilities across Maryland. Through her team's work, the American Cancer Society has provided an increasing number of uninsured and underinsured cancer patients with access to cancer information, day-to-day help and emotional support.

Eyring holds a Bachelor's degree in Health Science specializing in Community Health Education from Towson University. She resides in Baltimore County with her husband and two children.

Kathy Helzlsouer, M.D., M.H.S.

Kathy Helzlsouer, M.D., M.H.S. is a medical oncologist and epidemiologist. She is the director of the Prevention and Research Center at Mercy Medical Center and is an adjunct Professor of Epidemiology at the Johns Hopkins University Bloomberg School of Public Health. Her clinical work is focused on cancer risk assessment and prevention as well as improving the health of cancer survivors. The Prevention

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

and Research Center conducts clinical research which aims to reduce health disparities and improve the health and wellbeing of cancer patients.

William Nelson, M.D., Ph.D.

Dr. Nelson is the Marion I. Knott Professor of Oncology and Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is also a Professor of Urology, Pharmacology, Medicine, Pathology, and Radiation Oncology at the Johns Hopkins University School of Medicine, and holds a Joint Appointment in Environmental Health Sciences at the Johns Hopkins University Bloomberg School of Public Health.

Dr. Nelson completed his M.D. and Ph.D. training at the Johns Hopkins University School of Medicine, earning honors for both research and clinical excellence, and then pursued Internal Medicine residency training and Medical Oncology fellowship training at the Johns Hopkins Hospital, earning American Board of Internal Medicine certification in both disciplines. In addition to his administrative duties as Cancer Center Director, he directs a research laboratory focused on discovering new strategies for prostate cancer treatment and prevention. The laboratory has discovered the most common acquired genome change in cancer cells, a finding that has led to new approaches to prostate cancer detection, diagnosis, screening, and prevention.

Outside of Johns Hopkins, Dr. Nelson has become a recognized leader in translational cancer research. He was one of three Co-Chairs of the National Cancer-Institute Translational Research Working Group, which reported its findings to the National Cancer Advisory Board in June of 2007. A member of the American Association for Cancer Research, he has served as a member of the Board of Directors, the Clinical Research Committee, the Public Education Committee, the Special Conferences Committee, and the Science Policy and Legislative Affairs Committee. Dr. Nelson also served a term as the President of the National Coalition for Cancer Research, and is currently a member of the Scientific Advisory Boards of the Prostate Cancer Foundation and of Stand Up 2 Cancer, of the External Advisory Boards of six NCI-designated Cancer Centers, and of the Scientific Advisory Boards of several foundations supporting cancer research and several companies focused on the development of new technologies and treatments for human cancer. He is a Senior Editor of *Cancer Research* and an Associate Editor of *Clinical Cancer Research* and *Cancer Prevention Research*.

John E. Niederhuber, M.D.

John E. Niederhuber, M.D., joined Inova Health System as Executive Vice President and CEO of the Inova Translational Medicine Institute (ITMI) in September 2010. As leader of the ITMI, he directs a program that integrates technical innovation, informatics and sophisticated genomic analyses with the goal of managing disease risk and delivering excellence in individualized (personalized) healthcare, research and education. Within his first year at Inova, he initiated the ITMI Preterm Birth Study. This study involves the whole genome sequencing of 250 families (mother, father & baby) with the birth occurring less than 37 weeks gestation compared to 500 families with a full term normal pregnancy. The preterm birth study was completed in the first quarter of 2013 and is followed by the Fairfax County Longitudinal Childhood cohort study involving 2500 families launched in April 2012.

In 2006 Dr. Niederhuber was named by President George W. Bush to serve as the Director of the National Cancer Institute (NCI), one of the National Institutes of Health. Before assuming the directorship, he chaired the National Cancer Advisory Board and was Chief Operating Officer of the Institute.

During his tenure as NCI director, Dr. Niederhuber implemented many changes and despite successive years of less than inflation appropriations managed to initiate important new programs that shaped the Nation's investment in cancer to address areas that are likely to pay large health dividends. He began The

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

Cancer Genome Atlas, an effort to comprehensively identify the genomic changes in all major cancer types and subtypes. In addition to genomic studies of cancer and work in cancer immunotherapy, programs in nanobiology, systems biology, investigations into the tumor microenvironment, cancer initiating cells, and subcellular imaging benefited under his direction. Recognizing that 84% of cancer patients are cared for in their local communities, Dr. Niederhuber established the NCI Community Cancer Centers program to bring more patients into clinical trials, reduce healthcare disparities, and implement electronic medical records. In an effort to bring other scientific disciplines such as physicists and mathematicians together with cancer biologists to work on cancer, Dr. Niederhuber developed the funding for eight university centers that comprise the new Physical Sciences in Oncology Program.

He managed the NCI with more than 5,000 employees, over 2 million sq. ft. of space and an annual budget that eventually grew to over 5 billion dollars. He administered allocation of 1.2 billion dollars provided under the 2009 American Recovery and Reinvestment Act. He was the first NIH Institute director to increase intramural research utilizing a unique lease-back construction project for NCI's Advanced Technology Research Facility, Frederick, MD. He oversaw the successful negotiation of the new contractor to run the Government-owned Contractor-run (GoCo) research campus at NCI-Frederick. This Federally Funded Research and Development Contract is the only one in the U.S. devoted solely to biomedical research.

Dr. Niederhuber is recognized by his peers as a visionary leader in oncology. He daily puts into practice his expertise as both a cancer physician and a basic research scientist. His colleagues have acknowledged his leadership and accomplishments by electing him vice president and president of the Society for Surgical Oncology and president of the Association of American Cancer Institutes. He has served as a member of C-Change (a community of executives from government, business, and the non-profit community dedicated to conquering cancer) and as a member of the CEO Roundtable on Cancer. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Sciences, recognizing his outstanding scientific accomplishments and commitment to service in health sciences.

While at NCI, Dr. Niederhuber ran his own research program in the Laboratory of Tumor and Stem Cell Biology in NCI's Center for Cancer Research. His research focused on factors in the tumor microenvironment, in particular on cancer activated fibroblasts (CAFs) that lead to increased malignancy.

As a surgeon, Dr. Niederhuber's clinical focus has been on gastrointestinal cancer, hepatobiliary (liver, bile duct, pancreatic and gallbladder) cancer, and breast cancer. Recognized for his pioneering work in hepatic artery infusion chemotherapy, he was the first to demonstrate the feasibility of totally implantable vascular access devices which dramatically changed the administration of systemic chemotherapy.

He has given over 330 professional presentations and published over 230 peer-reviewed articles or book chapters as well as editing or co-editing 8 books. He currently serves as Managing Editor for the upcoming Abeloff's Clinical Oncology 5th Edition published by Elsevier Inc. He serves as a Director on the Boards of two publically traded biotechnology companies.

Prior to joining the NCI, Dr. Niederhuber was Director of the University of Wisconsin Comprehensive Cancer Center and a professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine. Earlier in his career, he chaired the Department of Surgery at Stanford University and held professorships at the Johns Hopkins University School of Medicine and at the University of Michigan.

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

A native of Steubenville, Ohio, Dr. Niederhuber is a graduate of Bethany College in West Virginia (receiving an honorary doctorate in 2007) and The Ohio State University School of Medicine. He trained in surgery at the University of Michigan.

Samuel Onyewu, M.D.

Dr. Onyewu, a graduate of Obafemi Awolowo University, Ile-Ife, Nigeria, has enormous interest in cancer related health disparities. He has been actively involved in outcomes research on cancer related disparities under the mentorship of Dr. Lori Wilson MD FACS at Howard University Hospital, department of surgery.

As part of his desire to bridge the gap of healthcare disparities among underserved populations, Dr. Onyewu has volunteered to be a research coordinator at AWCAA- A non-profit organization geared to address African immigrant women's unmet cancer needs. His goal is to propagate their endeavors through outreach programs, grant proposal development along with publications and presentations at conferences.

Dr. Onyewu is an associate member of American Association for Cancer Research, member American Medical Association, affiliate member American College of Surgeons, and is aspiring to become a surgeon, who will ultimately impact the lives of underprivileged and underserved populations both locally and internationally.

Paul Parker

Paul Parker is the Director of the Center for Health Care Facilities Planning and Development of the Maryland Health Care Commission, supervising facility and service planning and policy analysis and Certificate of Need regulation of capital investment by health care facilities. From 2006 to 2012, he served as the Center's Chief for Hospital Policy and Certificate of Need. Prior to joining the Maryland Health Care Commission in 2001, Paul worked as a medical facilities planning and regulatory consultant for health care facilities and physician groups. He directed the Virginia Certificate of Need program, from 1991 to 1999, and worked in private sector hospital planning and retirement community development for several firms in the 1980s, including the Marriott Corporation. He is a graduate of Indiana University, with a baccalaureate degree in Political Science and a graduate degree in Public Affairs with a concentration in Health Systems Administration. He serves on the Board of Directors of the American Health Planning Association.

Elizabeth A. Platz, Sc.D., M.P.H.

Dr. Elizabeth A. Platz is a Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and in the James Buchanan Brady Urological Institute. She is the Martin D. Abeloff, MD Scholar in Cancer Prevention and the Co-Leader of the Cancer Prevention & Control Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Platz is a leader in the field of cancer epidemiology and is recognized for her leadership of multidisciplinary prostate cancer research teams. A major focus of her work is the use of molecular and genetic epidemiology approaches to understand the mechanisms underlying prostate incidence and progression. She conducts her work with an eye toward translation of findings into prevention and treatment strategies. She is at the forefront of epidemiologic research on the role of inflammation, a target for prevention, in the development of prostate cancer, and on telomere length as a prognostic marker for poor outcome after treatment for prostate cancer.

Dr. Platz co-chaired the committee that developed the prostate cancer chapter for the most recent Maryland Comprehensive Cancer Control Plan, serves on the Maryland Cancer Collaborative Steering Committee, and chairs its Primary Prevention Committee. Starting in January 2014, she will become the chair of the Maryland Cancer Collaborative. She is also a member of Maryland's Prostate Medical

The 20th Annual Maryland State Council on Cancer Control Cancer Conference
Tuesday, November 19, 2013

Anne Arundel Health System Doordan Health Sciences Institute, 2000 Medical Parkway, Annapolis, MD 21401

Advisory Committee. She was born in Baltimore, raised in Maryland, and after completing her training, returned to Baltimore city, where she has resided since 1999.

Joshua M. Sharfstein, M.D.

Dr. Joshua M. Sharfstein was appointed by Governor Martin O'Malley as Secretary of the Maryland Department of Health and Mental Hygiene in January 2011.

In March 2009, President Obama appointed Dr. Sharfstein to serve as the Principal Deputy Commissioner of the U.S. Food and Drug Administration, the agency's second highest-ranking position. He served as the Acting Commissioner from March 2009 through May 2009 and as Principal Deputy Commissioner through January 2011.

From December 2005 through March 2009, Dr. Sharfstein served as the Commissioner of Health for the City of Baltimore, Maryland. In this position, he led efforts to expand literacy efforts in pediatric primary care, facilitate the transition to Medicare Part D for disabled adults, engage college students in public health activities, increase influenza vaccination of healthcare workers, and expand access to effective treatment for opioid addiction. Under his leadership, the Baltimore Health Department and its affiliated agencies have won multiple national awards for innovative programs, and in 2008, Dr. Sharfstein was named Public Official of the Year by *Governing Magazine*.

From July 2001 to December 2005, Dr. Sharfstein served as minority professional staff of the Government Reform Committee of the U.S. House of Representatives for Congressman Henry A. Waxman. Dr. Sharfstein is a 1991 graduate of Harvard College, a 1996 graduate of Harvard Medical School, a 1999 graduate of the combined residency program in pediatrics at Boston Children's Hospital and Boston Medical Center, and a 2001 graduate of the fellowship in general pediatrics at the Boston University School of Medicine.